Entasis Therapeutics Holdings Inc. – NASDAQ:ETTX

Add to watchlist

$2.19

Market closed

Open in about 13 hours

+17.74%

quarter

-11.34%

year

Market Cap	N/A
Enterprise value	90.10M

P/E	-1.95
EV/Sales	N/A
EV/EBITDA	-1.03
Price/Sales	N/A
Price/Book	6.29
PEG ratio	-0.03
EPS	-1.87

Revenue	N/A
EBITDA	-86.71M
Income	-86.83M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Profit margin
Jun 2021	0	-12.03M
Sep 2021	0	-12.39M
Dec 2021	0	-47.14M
Mar 2022	0	-15.27M

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Earnings per share (EPS)
2021-11-04	-0.26	-0.26
2022-03-03	-0.27	-0.25
2022-04-27	-0.26	-0.32

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Debt to assets
Jun 2021	63565000	10.50M	16.53%
Sep 2021	50766000	9.53M	18.77%
Dec 2021	40920000	9.70M	23.72%
Mar 2022	44090000	27.44M	62.24%

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Cash Flow
Jun 2021	-8.48M	-22K	19.97M
Sep 2021	-12.09M	-37K	-147K
Dec 2021	-12.29M	0	475K
Mar 2022	-13.75M	-9K	15M

Entasis Therapeutics Holdings alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Entasis Therapeutics Holdings
Employees

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Employee count
Aug 2023	51
Sep 2023	51
Oct 2023	51
Nov 2023	51
Dec 2023	51
Jan 2024	51
Feb 2024	51
Mar 2024	51
Apr 2024	51
May 2024	51
Jun 2024	51
Jul 2024	51

Entasis Therapeutics Holdings
Insider Trading

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX): Insider trades (number of shares)
Period	Buy	Sel
Oct 2021	0	34770
Jul 2022	7598814	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	11 Jul 2022	INNOVIVA, INC. other other	Common Stock	7,598,814	$2.2	$16,717,391
Sale	19 Oct 2021	PERROS MANOUSSOS director, officer..	Common Stock	11,974	$3.19	$38,197
Sale	19 Oct 2021	GUTCH MICHAEL officer: Chief Financial Officer and Chief B.. officer: Chief Financial Office..	Common Stock	3,759	$3.19	$11,991
Sale	19 Oct 2021	MUELLER JOHN PATRICK officer: Chief De..	Common Stock	4,001	$3.19	$12,763
Sale	19 Oct 2021	KEILEY ELIZABETH M officer: General Counsel officer: General Counsel	Common Stock	3,759	$3.19	$11,991
Sale	19 Oct 2021	TOMMASI RUBEN officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	3,759	$3.19	$11,991
Sale	19 Oct 2021	RONSHEIM MATTHEW officer: Chief of Pharmaceutical Sciences.. officer: Chief of Pharmaceutica..	Common Stock	3,759	$3.19	$11,991
Sale	19 Oct 2021	ALTARAC DAVID officer: Chief Me..	Common Stock	3,759	$3.19	$11,991
Purchase	11 Jun 2021	INNOVIVA, INC. 10 percent owner 10 percent owner	Common Stock	6,268,975	N/A	N/A
Purchase	3 May 2021	INNOVIVA, INC. 10 percent owner 10 percent owner	Common Stock	3,731,025	N/A	N/A

ETTX insider trading transactions

Entasis Therapeutics Holdings
Earnings Call Transcripts

Quarter	Transcript
Q2 2021 12 Aug 2021	Q2 2021 Earnings Call Transcript

ETTX earnings call transcripts

Entasis Therapeutics Holdings
Executives

Insider	Age	Compensation
Dr. Manoussos Perros (1968) Pres, Chief Executive Officer & Director	57	$934,850
Dr. David Altarac (1961) Chief Medical Officer	64	$598,290
Dr. John Patrick Mueller Ph.D. (1960) Chief Devel. Officer	65	$584,550

Entasis Therapeutics Holdings
Latest News

Monday, 20 May 2024
00:21	Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	https://www.businesswire.com
Friday, 8 July 2022
08:35	Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.	businesswire.com
08:35	Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.	businesswire.com
Friday, 3 June 2022
11:30	Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX	businesswire.com
11:30	Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX	businesswire.com
Tuesday, 24 May 2022
18:36	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.	prnewswire.com
16:34	Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva	Zacks Investment Research
Monday, 23 May 2022
10:17	Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share	Benzinga
Wednesday, 16 March 2022
12:15	Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today	InvestorPlace
Saturday, 6 November 2021
15:50	Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 18 October 2021
16:05	Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial	GlobeNewsWire
Thursday, 23 September 2021
16:05	Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference	GlobeNewsWire
Monday, 20 September 2021
16:34	Making Money With Penny Stocks During a Stock Market Crash	PennyStocks
Thursday, 16 September 2021
14:28	Why Are Entasis Therapeutics Shares Moving Higher On Thursday?	Benzinga
Wednesday, 15 September 2021
16:01	Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 2 Aug 2021

Week In Review: Kumquat Signs $2 Billion U.S.-China Deal With Lilly For Novel Immune Drugs

Frequently Asked Questions (FAQ)

What's the price of Entasis Therapeutics Holdings stock today?

One share of Entasis Therapeutics Holdings stock can currently be purchased for approximately $2.19.
When is Entasis Therapeutics Holdings's next earnings date?

Unfortunately, Entasis Therapeutics Holdings's (ETTX) next earnings date is currently unknown.
Does Entasis Therapeutics Holdings pay dividends?

No, Entasis Therapeutics Holdings does not pay dividends.
What is Entasis Therapeutics Holdings's stock symbol?

Entasis Therapeutics Holdings Inc. is traded on the NASDAQ under the ticker symbol "ETTX".
What is Entasis Therapeutics Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Entasis Therapeutics Holdings?

Shares of Entasis Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Entasis Therapeutics Holdings's key executives?
Entasis Therapeutics Holdings's management team includes the following people:
- Dr. Manoussos Perros Pres, Chief Executive Officer & Director(age: 57, pay: $934,850)
- Dr. David Altarac Chief Medical Officer(age: 64, pay: $598,290)
- Dr. John Patrick Mueller Ph.D. Chief Devel. Officer(age: 65, pay: $584,550)
How many employees does Entasis Therapeutics Holdings have?

As Jul 2024, Entasis Therapeutics Holdings employs 51 workers.
When Entasis Therapeutics Holdings went public?

Entasis Therapeutics Holdings Inc. is publicly traded company for more then 6 years since IPO on 26 Sep 2018.
What is Entasis Therapeutics Holdings's official website?

The official website for Entasis Therapeutics Holdings is entasistx.com.
Where are Entasis Therapeutics Holdings's headquarters?

Entasis Therapeutics Holdings is headquartered at 35 Gatehouse Dr, Waltham, MASSACHUSETTS.
How can i contact Entasis Therapeutics Holdings?

Entasis Therapeutics Holdings's mailing address is 35 Gatehouse Dr, Waltham, MASSACHUSETTS and company can be reached via phone at +1 781 810 0120.

Entasis Therapeutics Holdings Inc.

entasistx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

+1 781 810 0120

35 Gatehouse Dr
Waltham, MASSACHUSETTS 02451

CIK: 0001724344
ISIN: US2936141033
CUSIP: 293614103